Search for content, post, videos

Procuritas has taken a majority stake in Nordic Biomarker

Rikard Rodén

Nordic Biomarker is partnering with private equity company Procuritas.

”Together with our new Swedish majority owner Procuritas, who share our vision for the company to become a leading global supplier of products for reliable coagulation diagnostics, we are now in a better position than ever before to continue to grow and to expand our product portfolio for coagulation diagnostics. We look forward to this partnership and a successful journey together!” says Rikard Rodén, CEO at Nordic Biomarker.

In 2017, Nordic Biomarker teamed up with Medirox to provide an even broader range of routine and specialty reagents for IVD coagulation testing, offering both OEM products and CE-marked reagent kits. Nordic Biomarker had a revenue of 131M SEK in 2021 and has approximately 80 employees.

“With our ageing population and the trend towards science-based health testing, we see great opportunities for Nordic Biomarker to continue its impressive journey. The company has high-quality products for patients, and holds a unique and competitive position in a growing market. There are strong organic growth initiatives in place as well as exciting potential for M&A, so we see a great future for this business,” says Johan Conradsson, Co-Managing Partner at Procuritas.

Photo of Rikard Rodén: Nordic Biomarker